A two dose combined hepatitis A and B vaccine in Chinese youngsters

Lee, Shou‐Dong; Chan, Cho‐Yu; Yu, May-Ing; Wang, Yuan‐Jen; Chang, Full‐Young; Lo, Kwang‐Juei; Safary, Assad

doi:10.1002/(sici)1096-9071(199909)59:1<1::aid-jmv1>3.0.co;2-f

Cited by 22 publications

(10 citation statements)

References 14 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five to 10 years after primary vaccination, all children (100%) remained seropositive for anti-HAV [10,15,47,53]. After the second dose (month 7), GMC was 3701-14790.1 mIU/ml [10,15,38,41,47,48,[50][51][52][53][54]. Long-term follow-up data showed that GMC decreased over the years, but remained above the seropositivity cut-off up to 10 years follow-up [10,15,47,53].…”

Section: Ambirix Tmmentioning

confidence: 98%

“…The most reported solicited systemic reactions were fever, fatigue, and headache (Table 12). The percentage of participants experiencing unsolicited AEs ranged between 0% and 30.2% [41,48,50,54]. The kind of unsolicited event was not reported.…”

Section: Ambirix Tmmentioning

confidence: 98%

“…The anti-HAV seropositivity rates were equal for both vaccines in all studies. Anti-HAV antibody GMC was equal or higher following full vaccination with Twinrix TM or Ambirix TM compared to full vaccination with Havrix TM or unspecified hepatitis A vaccines [35,50,51]. Twinrix TM was equal or higher than other monovalent hepatitis B vaccines with regard to the anti-HBs response (Tables 9-11 ≥1 mIU/ml).…”

Section: Twinrix Tm Vs Monovalent Hepatitis a And B Vaccinesmentioning

confidence: 98%

“…In one study, anti-HBs seropositivity was measured and was 93.9% after full vaccination [50], and seroprotection rates ranged from 91.8% to 100% [38,41,[48][49][50][51][52][53][54]. Seroprotection rates decreased to at least 81.7% 10 years after primary vaccination [10,15,47,53].…”

Section: Ambirix Tmmentioning

confidence: 99%

“…Seroprotection rates decreased to at least 81.7% 10 years after primary vaccination [10,15,47,53]. GMC ranged from 1524 to 32540 mIU/ml 7 months after primary vaccination [38,41,48,[50][51][52][53][54]. After 10 years GMC decreased to 50.6-80.7 mIU/ml [15,53].…”

Section: Ambirix Tmmentioning

confidence: 99%

See 4 more Smart Citations

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

Bakker¹,

Bunge²,

Marano

et al. 2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Background: Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. Objective: To describe the vaccine efficacy, immunogenicity, effectiveness and safety of the combined vaccine against hepatitis A and hepatitis B. Methods: A systematic review of the literature published between 1990 and 2015.Results: Anti-HAV seropositivity rates ranged from 96.2% to 100% and anti-HBs seroprotection rates from 82% to 100%. Antibodies persisted up to 15 years and geometric mean concentration (GMC) remained above the seropositivity cut-off value for both. Anti-HAV and anti-HBs immune responses were lower in less immunocompetent individuals one month after completion of the immunization schedule. The safety profiles of Twinrix TM and monovalent hepatitis A and B vaccines were similar. Conclusion: The vaccine offers satisfactory long-term immunogenicity rates, expected duration of protection and safety profile similar to the monovalent hepatitis A or B vaccines.

show abstract

Section: Ambirix Tmmentioning

confidence: 98%

Section: Ambirix Tmmentioning

confidence: 98%

Section: Twinrix Tm Vs Monovalent Hepatitis a And B Vaccinesmentioning

confidence: 98%

Section: Ambirix Tmmentioning

confidence: 99%

Section: Ambirix Tmmentioning

confidence: 99%

See 3 more Smart Citations

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

Bakker¹,

Bunge²,

Marano

et al. 2016

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

Hepatitis A immunisation in persons not previously exposed to hepatitis A

Irving

Holden

Yang

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Follow-up: 12 to 17 months Non-serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH-GCP 1997 See comment See comment Insufficient evidence *The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio. GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. Cochrane Library Trusted evidence. Informed decisions. Better health.

show abstract

Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine

Damme¹,

Leroux‐Roels

Crasta

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

A combined hepatitis A and B vaccine is available since 1996. Two separate open-label primary studies evaluated the immunogenicity and safety of this hepatitis A and B vaccine (720 EI.U of HAV and 20 µg of HBsAg) in 306 healthy subjects aged 17-43 years who received three doses of the vaccine following a 0, 1, and 6 months schedule. These subjects were followed up annually for the next 15 years to evaluate long-term persistence of anti-HAV and anti-HBs antibodies. The subjects whose antibody concentrations fell below the cut-offs between Year 11 and Year 15 (anti-HAV: <15 mIU/ml; anti-HBs: <10 mIU/ml) were offered an additional dose of the appropriate monovalent hepatitis A and/or B vaccine. In subjects who received the additional vaccine dose, a blood sample was collected 1 month after vaccination. At the Year 15 time point, all subjects in Study A and Study B were seropositive for anti-HAV antibodies and 89.3% and 92.9% of subjects in the respective studies had anti-HBs antibody concentrations ≥10 mIU/ml. Four subjects (two in each study) received an additional dose of monovalent hepatitis B vaccine and mounted anamnestic responses to vaccination. No vaccine-related serious adverse events were reported. This study confirms the long-term immunogenicity of the three-dose regimen of the combined hepatitis A and B vaccine, as eliciting long-term persistence of antibodies and immune memory against hepatitis A and B for up to at least 15 years after a primary vaccination.

show abstract

A two dose combined hepatitis A and B vaccine in Chinese youngsters

Cited by 22 publications

References 14 publications

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

Hepatitis A immunisation in persons not previously exposed to hepatitis A

Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine

Contact Info

Product

Resources

About